KRAS mutational testing in metastatic CRC is part of a standard care to select patients to treatment targeting the EGFR as the presence of a KRAS mutation predicts for insensitivity to the anti-EGFR antibodies [16–18], and BRAF mutation also predicts a lack of benefit from anti-EGFR therapy [19]. This evidence concerns the gene EGFR and colorectal carcinoma.